Haemonetics (NYSE: HAE) reported Q3 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $260 million versus the consensus estimate of $266.94 million.

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.45-$2.55, versus the consensus of $2.53.

For earnings history and earnings-related data on Haemonetics (HAE) click here.